



Graphene Frontiers

Bruce Willner
Chief Science Officer

<http://www.graphenefrontiers.com>

Characterizing Disruptive Innovation: Meet the 'Disruptors'

The Disruption Myth and Gaps in the Innovation Ecosystem


Government-University-Industry Research Roundtable Meeting

National Academies, Washington, DC


October 20-21, 2015



Government | University | Industry
RESEARCH ROUNDTABLE



Today's Process – Clinical Laboratory Tests



Wait days for Results (or longer).


- Requires sending samples to a laboratory.
- The analysis is time-consuming, requiring several wet laboratory steps conducted by a skilled laboratory technician.
- Higher sensitivity, quantified results may take longer, if possible at all.

1st Gen POC Diagnostics: **Not Good Enough**

Typical samples



Common test formats



- **Limited sensitivity**
- **Inaccurate**
- **Slow**

Next Gen POC Diagnostics: Quantum Leap

Samples

Capillary blood, oral fluid, urine, breath, and other samples

Multiple test formats

Handheld lab-on-a-chip devices
Disposable tests (no instruments)
Doctor's office desk-based devices



Devices will fully automate testing and analysis or display of results




Transmission of results

Devices are likely to have wireless connectivity to transmit result data




Graphene Biosensor




GFET = Graphene Field Effect Transistor

Graphene Structure

- Hexagonal structure
- Short, strong bonds 1.42Å



Graphene Properties



Two Dimensional

Highly sensitive

Inert with Few Defects

Highly specific

Conductive


Strong signal


Strong

Robust devices

Make it ideal for biosensing applications...


GFET Functionalization







Biosensor Features

- Devices fabricated by IC lithography processes.
- Compact active area.
- High density arrays.
- Highly scalable production
- Device Array Integration for a Lab-on-a-chip



Example Results: Naltrexone Detection




Clear signal to picograms per milliliter

Lerner, M. B., et al. (2014). Nano Letters, 14(5), 2709–2714.

Demonstrated Results: **Multiple Proteins**

- **IL-6**
- **Troponin I**
- **Borrelia burgdorferi**
- **Osteopontin (OPN)**
- **Salmonella**

Signal @ 1pg/mL (30 fM)



Biosensors:


\$20B



*The Disruption Myth and Gaps in the Innovation Ecosystem
National Academies, Washington, DC October 20-21, 2015*



Global Multiplexed Diagnostics Market Revenue, By Technology, 2012 (USD Million)




Source: KOL Opinions, Company Annual Reports, Expert Interviews, Investing Publications, Press Releases & TMR Analysis

Low/Medium Density Multiplexed Assays:

>\$2B

Comparison with ELISA



	ELISA	GFET
Limit of Detection (LOD)	1-20pg/ml	100x-1000x better than ELISA ✓
Ability to Multiplex	No (1 antibody per run)	Yes ✓
Speed	<u>Hours</u> for incubation and processing	Sample to results in <u>minutes</u> ✓
Cost	Expensive Optical Readers	All electronic, lower cost ✓
Ease of Use	Trained <u>Lab Tech Needed</u>	After sample obtained, the rest is <u>automated</u> ✓
Specificity of detection	Relies on secondary detection antibody <u>Higher false positives</u>	Specific and direct detection – all electronic ✓

Go To Market: **Path to Revenue**

1. Research Use Only

- **Currently available through Sigma-Aldrich**

2. Real-time Biomonitor

3. Point of Care Diagnostics

- **Developed and distributed via partners***

Commercialization Challenges

Point of Care Diagnostics is the large application.


Challenges:

- A large, established industry.
- Healthcare industry does not like change.
- Many different tests for many different conditions.
- Approval path is slow and expensive and needs to be repeated for each test.
- Revenue Path is critical (i.e. HCPCS Codes)

Our Solution:

- Begin targeting diagnostic tests with impact.
- Partner with existing diagnostic companies.
- Focus our work on our expertise and team with others for our shortcomings.

Proof of Concept Program: Troponin I



POC Diagnostics: Potential Partners



Company Origin

- Spin-out from the University of Pennsylvania.
 - Formed in 2011
- Formed around IP for low-cost, production of graphene films (developed in the Physics Department lab of A.T. Charlie Johnson).
- Additional graphene production technology developed at Graphene Frontiers.



Problem: Commercial Production



1) Low Volume


2) Expensive



3) Not Uniform

4) Harsh Chemicals

Breakthrough: Problem Solved!




- Developed Processes For:
- Scalable single atomic layer graphene deposition
- Graphene handling
 - Transfer of the graphene to different substrates.





National Science Foundation
WHERE DISCOVERIES BEGIN


Graphene Chemical Vapor Deposition





Atmospheric Pressure Chemical Vapor Deposition



Continuous Graphene Transfer




- Hydrolysis-Assisted Mechanical Separation



Scaled Graphene Production

2010



$1 \text{ cm}^2 > \$10,000$

2012




$1 \text{ cm}^2 < \$10$


2016



$1 \text{ cm}^2 < \$0.01$



Markets: Size and Timing



Market
Ready:



The Disruption Myth and Gaps in the Innovation Ecosystem
National Academies, Washington, DC October 20-21, 2015



Thank You




Graphene
Frontiers



six sensors
elevate your platform


Bruce Willner - Chief Science Officer

<http://www.graphenefrontiers.com>




Rigid Substrate Transfer


- Transfer to rigid surfaces using an intermediate transfer substrate.
- Patterned Transfer
 - Pattern the graphene through selective adhesion of the graphene.



Vapor Phase Detection



Vapor Phase Detection



Kybert, N., et al (2014). *Nano Research*, 7(1), 95–103.